September 30, 2022
Loading...
You are here:  Home  >  Health Care & Life Science  >  Current Article

Amgen’s gamble on new cancer drug may pay off

IN THIS ARTICLE

Amgen co-founder William K. Bowes Jr. stands watch over the Thousand Oaks campus. When Amgen bought Onyx Pharmaceuticals for $10.4 billion in 2013, it banked on Kyprolis becoming a mainstream cancer drug to treat multiple myeloma. Amgen may soon find out whether that gamble pays off. Kyprolis is currently approved for third-line treatments, and the…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.